PRQR: ProQR Cash per Share

Corporate emblem and logo of ProQR (PRQR)

ProQR Therapeutics N.V. (PRQR) generates revenue through royalties and upfront payments from partners by developing RNA therapies for eye and liver diseases. The annual trend of cash per share illustrates the asset's liquidity, where the 0.82 level reflects the status of the parameter. While molecule development remains independent of economic cycles, the lack of commercial sales and high R&D expenditures leave the company dependent on external financing.

PRQR: ProQR Therapeutics Cash per Share 07/04/2022 - 11/20/2026

Analytical breakdowns for ProQR Therapeutics N.V.

- market price and analyst price targets:
- cash position and cash flow details:
General company analysis:ProQR - PRQR
Signature product of proqr.com

Developing RNA therapies in partnership with pharmaceutical behemoths requires significant funding to support long-term scientific alliances. The cash per share trend captures the specific volume of liquid capital per security, allowing for a real-time assessment of the budget's actual resilience and the efficiency of resource management to ensure the stability of ProQR Therapeutics N.V. (PRQR) during the creation of new drugs.

Analysis of competing companies

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Intellia|Stoke - Cash per Single Share|BLFS: Cash Funds per Single Share|Wave Life Sciences Corp - Cash per Share|Maze Therapeutics, Inc. (MAZE) - Cash per Single Share|Sionna Therapeutics Inc (SION) - Cash Funds per Share|Cash per Single Share Prime Medicine Corp|Cash Funds per Share tayshagtx.com|QURE - Cash Funds Volume per Share|Cash per Single Share MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Cash Funds Volume per Share|Cash per Share SLDB (Solid Biosciences Inc.)|Amount of Cash per Share OCGN|PacBio Corp - Cash per Share|Benitec Biopharma Inc. (BNTC) - Cash per Single Share|DSGN: Cash per Share|Cash Funds per Single Share RCKT|Cash per Single Share FDMT|Cash Funds per Single Share LXEO (Lexeo Therapeutics)|Cash per Share KRRO|Editas Medicine, Inc. - Cash Funds per Single Share|Cash Funds per Share Silence Therapeutics Inc. SLN|CDXS - Cash per Single Share|Sangamo Therapeutics Inc. - Cash per Share|NAUT - Cash per Share|MGX: Cash per Share|Cash per Single Share Precision BioSciences, Inc.|GBIO (Generation Bio) - Cash per Share|Boundless Bio Inc. (BOLD) - Cash Funds Calculated per Share|Cash per Single Share XCUR (exicuretx.com)|Imunon Inc - Cash Funds per Single Share|Cash per Share PHIO (Phio Pharmaceuticals Corp)|Amount of Cash per Share MBIO|RNAZ - Cash Funds per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology